MX2012002855A - Terapia de cancer dirigida a celula madre de cancer y resistente a farmaco. - Google Patents

Terapia de cancer dirigida a celula madre de cancer y resistente a farmaco.

Info

Publication number
MX2012002855A
MX2012002855A MX2012002855A MX2012002855A MX2012002855A MX 2012002855 A MX2012002855 A MX 2012002855A MX 2012002855 A MX2012002855 A MX 2012002855A MX 2012002855 A MX2012002855 A MX 2012002855A MX 2012002855 A MX2012002855 A MX 2012002855A
Authority
MX
Mexico
Prior art keywords
drug resistant
stem cell
cancer
targeted
cancer stem
Prior art date
Application number
MX2012002855A
Other languages
English (en)
Inventor
Angelika Burger
Original Assignee
Kominox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox Inc filed Critical Kominox Inc
Publication of MX2012002855A publication Critical patent/MX2012002855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

La presente invención proporciona métodos para prevenir, tratar y/o manejar cáncer, el método que comprende administrar a un sujeto en necesidad del mismo una cantidad terapéuticamente efectiva de meta arsenito de sodio que reduce o elimina las poblaciones de células madre de cáncer resistentes a fármaco así como las células de cáncer maduras resistentes a fármaco.
MX2012002855A 2009-09-10 2010-09-09 Terapia de cancer dirigida a celula madre de cancer y resistente a farmaco. MX2012002855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10
PCT/US2010/048308 WO2011031890A2 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Publications (1)

Publication Number Publication Date
MX2012002855A true MX2012002855A (es) 2012-07-20

Family

ID=43647965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002855A MX2012002855A (es) 2009-09-10 2010-09-09 Terapia de cancer dirigida a celula madre de cancer y resistente a farmaco.

Country Status (24)

Country Link
US (1) US20110059186A1 (es)
EP (1) EP2475362B1 (es)
JP (1) JP5710619B2 (es)
KR (2) KR101721009B1 (es)
CN (2) CN107412771A (es)
AR (1) AR079000A1 (es)
AU (1) AU2010292192B2 (es)
BR (1) BR112012008315B1 (es)
CA (1) CA2772411C (es)
CY (1) CY1121973T1 (es)
DK (1) DK2475362T3 (es)
ES (1) ES2723778T3 (es)
HU (1) HUE043387T2 (es)
IN (1) IN2012DN02008A (es)
LT (1) LT2475362T (es)
MX (1) MX2012002855A (es)
PL (1) PL2475362T3 (es)
PT (1) PT2475362T (es)
RU (1) RU2568834C2 (es)
SG (2) SG10201608967WA (es)
SI (1) SI2475362T1 (es)
TR (1) TR201905548T4 (es)
TW (1) TWI564012B (es)
WO (1) WO2011031890A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
WO2012131487A2 (en) * 2011-03-30 2012-10-04 Kominox, Inc. Compositions and methods for the treatment of cancer
WO2015046783A1 (en) 2013-09-30 2015-04-02 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
CN110719790A (zh) * 2017-05-24 2020-01-21 加利福尼亚大学董事会 治疗癌症的反义疗法
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DE69434093T2 (de) * 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
CA2307208A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
ES2399480T3 (es) * 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
CA2481602C (en) * 2002-04-10 2011-06-21 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
MX2012002922A (es) * 2009-09-18 2012-09-07 Kominox Inc Metodos para tratar tumores del cerebro.

Also Published As

Publication number Publication date
AU2010292192B2 (en) 2015-04-02
CN107412771A (zh) 2017-12-01
TR201905548T4 (tr) 2019-05-21
RU2568834C2 (ru) 2015-11-20
RU2012108144A (ru) 2013-10-20
TWI564012B (zh) 2017-01-01
AR079000A1 (es) 2011-12-21
JP2013504587A (ja) 2013-02-07
KR20120061908A (ko) 2012-06-13
BR112012008315A2 (pt) 2016-09-13
CA2772411C (en) 2017-08-22
ES2723778T3 (es) 2019-09-02
CN102753164A (zh) 2012-10-24
LT2475362T (lt) 2019-06-10
WO2011031890A2 (en) 2011-03-17
EP2475362B1 (en) 2019-03-27
JP5710619B2 (ja) 2015-04-30
AU2010292192A1 (en) 2012-03-29
IN2012DN02008A (es) 2015-07-24
PT2475362T (pt) 2019-05-27
WO2011031890A3 (en) 2011-08-25
BR112012008315B1 (pt) 2021-08-03
CA2772411A1 (en) 2011-03-17
EP2475362A2 (en) 2012-07-18
DK2475362T3 (da) 2019-06-03
US20110059186A1 (en) 2011-03-10
CY1121973T1 (el) 2020-10-14
KR20150038702A (ko) 2015-04-08
PL2475362T3 (pl) 2019-09-30
KR101721009B1 (ko) 2017-03-29
WO2011031890A4 (en) 2011-10-13
EP2475362A4 (en) 2013-03-27
SI2475362T1 (sl) 2019-08-30
TW201114430A (en) 2011-05-01
SG10201608967WA (en) 2016-12-29
HUE043387T2 (hu) 2019-08-28
SG179069A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
AU2011328009A8 (en) Compounds and methods for treating pain
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
MX2013003076A (es) Terapeuticos contra cancer de mama.
MX345494B (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
MX2014000150A (es) Sistemas, metodos y formulaciones para tratamiento de cancer.
SG179192A1 (en) Methods for treating brain tumors
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
IN2014DN08385A (es)
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
SG195170A1 (en) Methods of treating or preventing rheumatic disease
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
EP2568990A4 (en) METHOD OF PRODUCING PLEURODESIS
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
MX2011012668A (es) Metodos de administracion de compuestos agonistas de trombopoyetina.
UA71039U (ru) Способ премедикации у онкологических больных

Legal Events

Date Code Title Description
FG Grant or registration